CNTB: Rapid FEV1 improvement and strong health economics support phase III plans for acute asthma
Seabreeze asthma data showed rapid, significant lung function improvement and validated prior findings, supporting phase III advancement. U.S. claims data reveal a large, economically significant acute asthma market, while regulatory discussions will focus on FEV1 as a primary endpoint.Based on Con…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.